Background A glycoprotein with a molecular weight of 25 kDa is known as neutrophil gelatinaseassociated lipocalin (NGAL). It is often detected in tiny amounts in many human organs. Aim of the research: To identify the profile of circulating NGAL in liver disease patients with different morbidities and also evaluate the potential for NGAL as a prognostic indicator for early identification of AKI in these individuals. Patients & methods: This cross-sectional research was performed on 230 cases with different liver diseases, selected from the inpatient and outpatient clinics in the hepatology and gastroenterology departments of the multicentric They were divided into four groups: Group A: nonalcoholic fatty liver disease patients (NAFLD), Group B: nonalcoholic steatohepatitis patients (NASH); Group C: compensated liver disease patients; and Group D: decompensated liver disease. Results There was a significant variance between different liver disease groups concerning NGAL. Thus, NGAL was significantly higher among NASH patients than compensated liver disease cases and decompensated liver disease cases among NAFLD patients. A significant positive association was noted among NGAL with creatinine and SGPT. Nevertheless, there was a significant negative association between NGAL and eGFR among NAFLD patients. NGAL yields a significant level at a cutoff level of >128 ng/ml in predicting renal impairment among decompensated liver disease cases, with a sensitivity of 96% and a specificity of 100%. Conclusion NGAL is a useful prognostic marker for early identification of acute kidney injuries in individuals with liver disease.